Browse the evidence

Long-term stable use of GLP-1 receptor agonists results in attenuated gastric emptying effects (tachyphylaxis) compared to recent initiation, reducing perioperative risk.

If you have been on your GLP-1 shot for months, your body has likely adapted, and your stomach empties more normally than when you first started. This makes surgery safer for you than for someone who just started the drug two weeks ago.

Synchronous remote weight management interventions for adults with excess weight (BMI ≥ 27.5 kg/m2) face significant engagement barriers including privacy concerns, time burden, technical issues, and digital exclusion, which can be mitigated by facilitators such as digital competency, tailored feedback, convenience, and professional support.

To succeed with a remote weight management program, prioritize platforms that offer strong privacy protections, ease of use, and professional support. Address technical barriers by ensuring you have reliable internet and basic digital skills. Leverage features like self-monitoring and tailored feedback to maintain engagement, as these are key facilitators identified in the research.

GIP receptor antagonism, when combined with GLP-1 receptor agonism, produces superior weight loss and glycemic control compared to GLP-1 receptor agonism alone.

Current research indicates that combining a GIP receptor antagonist with a GLP-1 agonist (like the investigational drug AMG133) leads to greater weight loss and better blood sugar control than using a GLP-1 agonist alone. This benefit is seen in clinical trials with sustained effects, though the exact mechanism of the GIP part's contribution to weight loss is not fully understood.

Tirzepatide, a dual GLP-1 and GIP agonist, significantly reduces Obstructive Sleep Apnea (OSA) severity and body weight in patients with moderate-to-severe OSA and obesity, marking the first FDA-approved pharmacotherapy for this condition.

If you have moderate-to-severe sleep apnea and obesity, tirzepatide is a new, FDA-approved option. It is a once-weekly injection that helps you lose significant weight (16-17%) and reduces your sleep apnea severity (AHI) by 20-24 events per hour. While it may cause temporary stomach issues, it offers a dual benefit for both your sleep and metabolic health.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events (MACE) and cardiovascular death in people with type 2 diabetes and established CVD.

GLP-1 receptor agonists are effective medications that reduce heart attack and stroke risk in people with diabetes or existing heart disease. Access is improving but remains a barrier due to cost.

Tirzepatide produces greater magnitude and faster velocity of weight loss compared to semaglutide in real-world clinical practice.

If you are choosing between Tirzepatide and Semaglutide for weight loss, Tirzepatide is associated with losing more weight (approx 4% more on average) and losing it faster in the first year. This is based on real-world data from over 20,000 patients.

Tirzepatide is associated with a lower prevalence of gastrointestinal and systemic adverse events compared to semaglutide, particularly in high responders.

If you are concerned about side effects like nausea or vomiting, Tirzepatide may be better tolerated than Semaglutide in real-world use, especially if you are a 'high responder' to the drug.

Demographic disparities exist in weight loss response to GLP-1RAs, with White and female patients more likely to be high responders, while Black and Hispanic patients are more likely to be minimal responders.

Be aware that real-world data shows White and female patients are more likely to achieve high weight loss with GLP-1RAs, while Black and Hispanic patients are more likely to have minimal weight loss. This highlights the need for personalized treatment strategies.

Sleeve gastrectomy (SG) induces metabolic changes beyond restriction by reducing ghrelin and increasing GLP-1 and GIP, which stimulates insulin release and delays gastric emptying to improve type 2 diabetes.

If you undergo sleeve gastrectomy, your body's hormone production changes to help control blood sugar and hunger, not just because your stomach is smaller. This metabolic shift is a key reason why type 2 diabetes often improves after this specific surgery.

GLP-1 and GIP receptor agonists reduce the composite incidence of death due to cardiovascular events, nonfatal myocardial infarction, and nonfatal stroke in patients with overweight or obesity.

If you have overweight or obesity, GLP-1 and GIP receptor agonists like semaglutide can reduce your risk of cardiovascular events, including death, heart attack, and stroke.

Endoscopic Sleeve Gastroplasty (ESG) is a highly cost-effective, less invasive alternative to surgery for Class I obesity, with an ICER well below willingness-to-pay thresholds.

For Class I obesity, ESG offers a durable, cost-effective alternative to surgery with a favorable safety profile. It is particularly valuable for patients who want more than lifestyle changes but are not candidates for or willing to undergo surgery.

In emerging economies like Vietnam, the rapid expansion of modern retail and increased availability of ultra-processed foods (UPFs) drives a shift toward unhealthy dietary patterns, contributing to rising obesity and diabetes rates.

For policymakers in emerging economies: Simply having traditional markets is not enough. You must actively regulate the expanding modern retail sector (supermarkets/convenience stores) through labeling, marketing restrictions, and fiscal incentives to ensure healthy food remains affordable and accessible compared to ultra-processed options.

Experts prioritize communication, education, and voluntary standards over strict regulatory constraints (like taxes or advertising bans) when designing food environment policies.

Policymakers should not rely solely on education and voluntary standards. To effectively combat the rise of UPFs, they must implement stricter regulatory measures like taxes and marketing restrictions, despite perceived feasibility challenges, as these are proven to be effective in other contexts.

A poly-metabolite score derived from serum and urine metabolomics can accurately predict and discriminate between high (80% energy) and low/zero (0% energy) ultra-processed food (UPF) intake in free-living populations.

Current dietary self-reporting methods for ultra-processed foods are prone to error and misclassification. This research identifies specific blood and urine metabolite patterns that serve as objective biomarkers for UPF intake. For researchers, these scores improve the accuracy of studying UPF's health impacts. For individuals, it underscores that 'ultra-processed' is a biological reality detectable in the body, not just a label on a package, highlighting the metabolic complexity introduced by industrial food processing.

Urolithin A supplementation (1000 mg/day for 4 weeks) significantly reduces indirect markers of muscle damage (creatine kinase) and ratings of perceived exertion following intense exercise in highly trained male distance runners, facilitating recovery without enhancing actual running performance.

If you are a highly trained male distance runner, taking 1000 mg of Urolithin A daily for 4 weeks may help you recover faster from hard workouts by reducing muscle damage markers and perceived exertion. However, do not expect this supplement to make you run faster in races. It supports recovery, not performance output.

Higher consumption of sugar-sweetened beverages (SSBs) is associated with a greater increase in type 2 diabetes risk compared to artificially sweetened beverages (ASBs).

If you must choose between sugary and artificially sweetened drinks, sugary drinks pose a much higher risk for type 2 diabetes. However, both are associated with increased risk compared to not drinking them. The best choice for diabetes prevention is water or unsweetened beverages.

Obesity should be managed as a chronic, relapsing disease with long-term structured medical interventions (pharmacotherapy, surgery, behavioral therapy) rather than relying on short-term lifestyle changes, mirroring the established management model for Type 2 Diabetes Mellitus (T2DM).

Stop treating obesity as a short-term lifestyle issue. Seek a healthcare provider who recognizes it as a chronic disease. This means expecting long-term management with evidence-based tools like GLP-1 receptor agonists (e.g., semaglutide, tirzepatide), behavioral therapy, and potentially surgery, rather than just being told to 'eat less and move more.'

Combining multiple receptor pathways (e.g., GLP-1/GIP, GLP-1/Amylin, or GLP-1/Glucagon) produces synergistic and superior weight loss compared to monotherapy, representing a historical inflection point in obesity pharmacotherapy.

Obesity is a chronic biological disease requiring physiological treatment, not just willpower. Modern combination therapies (targeting GLP-1, GIP, Amylin, or Glucagon receptors) are significantly more effective than older drugs or lifestyle changes alone, achieving 15-24% weight loss in trials. While access and cost are current barriers, these medications are designed to be used alongside lifestyle modifications to overcome biological forces promoting weight gain. Consult a provider about whether combination receptor agonists are appropriate for your health profile.

In patients with type 2 diabetes, initiating tirzepatide (a dual GIP/GLP-1 receptor agonist) results in significantly greater reductions in HbA1c and body weight compared to initiating injectable semaglutide (a GLP-1 receptor agonist) over a 12-month period, regardless of prior GLP-1 RA exposure.

If you have Type 2 Diabetes and are starting a GLP-1 based therapy, choosing tirzepatide over semaglutide is likely to result in better blood sugar control and more significant weight loss over the first year. This benefit holds true whether you have never used these drugs before or have tried semaglutide previously. The trade-off is managing the weekly injection schedule and potential side effects, but the metabolic gains are statistically superior.

In adults with prediabetes, a high-carbohydrate (50% energy) diet reduces fasting glucose more effectively than a reduced-carbohydrate (35% energy) diet when both are calorie-restricted, despite similar weight loss.

If you have prediabetes, you do not need to severely restrict carbohydrates to improve your fasting blood sugar. A diet providing about 50% of your calories from carbohydrates, focusing on high-fiber foods like whole grains and vegetables, can lower fasting glucose better than a lower-carb diet, provided you are in a calorie deficit. Focus on the quality of carbs (fiber) rather than just cutting them out.

Metabolic bariatric surgery (MBS) procedures, specifically Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG), single anastomosis duodenal-ileal bypass (SADI), and biliopancreatic diversion (BPD), provide superior long-term total body weight loss (TBWL) compared to obesity management medications (OMM) and endoscopic bariatric procedures (EBP).

If you are struggling with obesity and lifestyle changes alone have not provided sufficient long-term results, metabolic bariatric surgery (specifically RYGB, SG, SADI, or BPD) offers the highest probability of significant, sustained weight loss. While newer medications (semaglutide, tirzepatide) are excellent short-to-medium term options and comparable to surgery initially, surgery tends to maintain higher efficacy over the long term (3+ years). Consult a specialist to determine if you are a candidate for these procedures, especially if your BMI is >= 40 kg/m2.

Combined exercise and pharmacotherapy significantly reduces systolic and diastolic blood pressure and triglycerides compared to exercise alone, but does not significantly improve fasting glucose, HDL, or LDL.

While adding medication to exercise improves blood pressure and triglycerides, it may not significantly improve fasting glucose or cholesterol levels (HDL/LDL) compared to medication alone. Focus on the weight loss and blood pressure benefits.

The EMP16 combination therapy significantly improves the Fatty Liver Index (FLI) and reduces visceral adiposity index (VAI) more effectively than conventional orlistat, suggesting specific benefits for liver health beyond general weight loss.

If you have fatty liver or high visceral fat, this specific combination pill (EMP16) may offer better liver health improvements than standard orlistat. It significantly reduces the Fatty Liver Index compared to conventional treatments.

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) produce significant real-world weight loss, but effectiveness is substantially lower than in clinical trials due to high discontinuation rates (20-50%) and suboptimal dosing in routine care.

GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss, but their real-world success depends entirely on sticking with them. Many people stop early due to side effects or cost, leading to less weight loss than seen in trials. To get the best results, you must manage side effects (which often fade) and ensure you can afford the medication long-term. If you adhere to the full dose and stay on the drug, your weight loss can match what is seen in clinical trials.